Startseite>>Signaling Pathways>> Others>>Eslicarbazepine

Eslicarbazepine

Katalog-Nr.GC36008

Eslicarbazepin ist ein orales Antikonvulsivum, das zur Zusatzbehandlung von partiellen AnfÄllen indiziert ist.

Products are for research use only. Not for human use. We do not sell to patients.

Eslicarbazepine Chemische Struktur

Cas No.: 104746-04-5

Größe Preis Lagerbestand Menge
5mg
56,00 $
Auf Lager
10mg
93,00 $
Auf Lager
25mg
176,00 $
Auf Lager
50mg
269,00 $
Auf Lager
100mg
417,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

Eslicarbazepine is an anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. Eslicarbazepine acetate is a prodrug for eslicarbazepine (S-licarbazepine), which is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel[1][2].

References:
[1]. Finelli E, et al. Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction. Eur Ann Allergy Clin Immunol. 2018 Sep;50(5):229-231.
[2]. Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.

Bewertungen

Review for Eslicarbazepine

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eslicarbazepine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.